These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
475 related articles for article (PubMed ID: 33670427)
1. miR-582-5p Is a Tumor Suppressor microRNA Targeting the Hippo-YAP/TAZ Signaling Pathway in Non-Small Cell Lung Cancer. Zhu B; V M; Finch-Edmondson M; Lee Y; Wan Y; Sudol M; DasGupta R Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33670427 [TBL] [Abstract][Full Text] [Related]
2. A novel role for microRNA-129-5p in inhibiting ovarian cancer cell proliferation and survival via direct suppression of transcriptional co-activators YAP and TAZ. Tan G; Cao X; Dai Q; Zhang B; Huang J; Xiong S; Zhang Yy; Chen W; Yang J; Li H Oncotarget; 2015 Apr; 6(11):8676-86. PubMed ID: 25895125 [TBL] [Abstract][Full Text] [Related]
3. Targeting the Hippo Signaling Pathway for Tissue Regeneration and Cancer Therapy. Juan WC; Hong W Genes (Basel); 2016 Aug; 7(9):. PubMed ID: 27589805 [TBL] [Abstract][Full Text] [Related]
4. YAP/TAZ and EZH2 synergize to impair tumor suppressor activity of TGFBR2 in non-small cell lung cancer. Lo Sardo F; Pulito C; Sacconi A; Korita E; Sudol M; Strano S; Blandino G Cancer Lett; 2021 Mar; 500():51-63. PubMed ID: 33296708 [TBL] [Abstract][Full Text] [Related]
5. LncRNA SFTA1P mediates positive feedback regulation of the Hippo-YAP/TAZ signaling pathway in non-small cell lung cancer. Zhu B; Finch-Edmondson M; Leong KW; Zhang X; V M; Lin QXX; Lee Y; Ng WT; Guo H; Wan Y; Sudol M; DasGupta R Cell Death Discov; 2021 Nov; 7(1):369. PubMed ID: 34845189 [TBL] [Abstract][Full Text] [Related]
6. Down-Regulated microRNA-192-5p Protects Against Hypoxic-Ischemic Brain Damage via Regulation of YAP1-Mediated Hippo Signaling Pathway. Yan G; Tao Z; Xing X; Zhou Z; Wang X; Li X; Li F Neurochem Res; 2022 May; 47(5):1243-1254. PubMed ID: 35084661 [TBL] [Abstract][Full Text] [Related]
7. Suppression of microRNA-125a-5p upregulates the TAZ-EGFR signaling pathway and promotes retinoblastoma proliferation. Zhang Y; Xue C; Zhu X; Zhu X; Xian H; Huang Z Cell Signal; 2016 Aug; 28(8):850-60. PubMed ID: 27094723 [TBL] [Abstract][Full Text] [Related]
8. Yes-associated protein (YAP) and transcriptional coactivator with a PDZ-binding motif (TAZ): a nexus between hypoxia and cancer. Zhao C; Zeng C; Ye S; Dai X; He Q; Yang B; Zhu H Acta Pharm Sin B; 2020 Jun; 10(6):947-960. PubMed ID: 32642404 [TBL] [Abstract][Full Text] [Related]
9. Quantitative Real-Time PCR to Measure YAP/TAZ Activity in Human Cells. Cao X; Zhao B Methods Mol Biol; 2019; 1893():137-152. PubMed ID: 30565132 [TBL] [Abstract][Full Text] [Related]
10. Biological Significance of YAP/TAZ in Pancreatic Ductal Adenocarcinoma. Hayashi H; Uemura N; Zhao L; Matsumura K; Sato H; Shiraishi Y; Baba H Front Oncol; 2021; 11():700315. PubMed ID: 34395269 [TBL] [Abstract][Full Text] [Related]
11. MicroRNAs Regulating Hippo-YAP Signaling in Liver Cancer. Lee NH; Kim SJ; Hyun J Biomedicines; 2021 Mar; 9(4):. PubMed ID: 33808155 [TBL] [Abstract][Full Text] [Related]
12. Regulation of ferroptosis in cancer cells by YAP/TAZ and Hippo pathways: The therapeutic implications. Sun T; Chi JT Genes Dis; 2021 May; 8(3):241-249. PubMed ID: 33997171 [TBL] [Abstract][Full Text] [Related]
13. MCM7 and its hosted miR-25, 93 and 106b cluster elicit YAP/TAZ oncogenic activity in lung cancer. Lo Sardo F; Forcato M; Sacconi A; Capaci V; Zanconato F; Di Agostino S; Del Sal G; Pandolfi PP; Strano S; Bicciato S; Blandino G Carcinogenesis; 2017 Jan; 38(1):64-75. PubMed ID: 27797825 [TBL] [Abstract][Full Text] [Related]
14. MiR-33a Controls hMSCS Osteoblast Commitment Modulating the Yap/Taz Expression Through EGFR Signaling Regulation. Costa V; Carina V; Raimondi L; De Luca A; Bellavia D; Conigliaro A; Salamanna F; Alessandro R; Fini M; Giavaresi G Cells; 2019 Nov; 8(12):. PubMed ID: 31771093 [TBL] [Abstract][Full Text] [Related]
15. Emerging Role of Hippo-YAP (Yes-Associated Protein)/TAZ (Transcriptional Coactivator with PDZ-Binding Motif) Pathway Dysregulation in Renal Cell Carcinoma Progression. Mondal V; Higgins PJ; Samarakoon R Cancers (Basel); 2024 Aug; 16(15):. PubMed ID: 39123485 [TBL] [Abstract][Full Text] [Related]
16. The Hippo Signaling Core Components YAP and TAZ as New Prognostic Factors in Lung Cancer. Jiang Y; Xie WJ; Chen RW; You WW; Ye WL; Chen H; Chen WX; Xu JP Front Surg; 2022; 9():813123. PubMed ID: 35388363 [TBL] [Abstract][Full Text] [Related]
17. SKI activates the Hippo pathway via LIMD1 to inhibit cardiac fibroblast activation. Landry NM; Rattan SG; Filomeno KL; Meier TW; Meier SC; Foran SJ; Meier CF; Koleini N; Fandrich RR; Kardami E; Duhamel TA; Dixon IMC Basic Res Cardiol; 2021 Apr; 116(1):25. PubMed ID: 33847835 [TBL] [Abstract][Full Text] [Related]
18. Inhibition of Hippo Signaling Improves Skin Lesions in a Rosacea-Like Mouse Model. Lee J; Jung Y; Jeong SW; Jeong GH; Moon GT; Kim M Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33477764 [TBL] [Abstract][Full Text] [Related]
19. Cysteine S-Glutathionylation Promotes Stability and Activation of the Hippo Downstream Effector Transcriptional Co-activator with PDZ-binding Motif (TAZ). Gandhirajan RK; Jain M; Walla B; Johnsen M; Bartram MP; Huynh Anh M; Rinschen MM; Benzing T; Schermer B J Biol Chem; 2016 May; 291(22):11596-607. PubMed ID: 27048650 [TBL] [Abstract][Full Text] [Related]
20. miR-9-3p plays a tumour-suppressor role by targeting TAZ (WWTR1) in hepatocellular carcinoma cells. Higashi T; Hayashi H; Ishimoto T; Takeyama H; Kaida T; Arima K; Taki K; Sakamoto K; Kuroki H; Okabe H; Nitta H; Hashimoto D; Chikamoto A; Beppu T; Baba H Br J Cancer; 2015 Jul; 113(2):252-8. PubMed ID: 26125451 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]